As New Jersey’s only National Cancer Institute-designated Comprehensive Cancer Center, Rutgers Cancer Institute of New Jersey together with RWJBarnabas Health is the state’s leading authority on cancer. As such, we want to help our patients navigate and better understand how the coronavirus may impact them.
Dr. Gulhati received a Bachelor of Science in Physiology (Honors) from The University of British Columbia. As an undergraduate, he performed research in the laboratory of Dr. Poul Sorensen to identify novel interaction partners of the chimeric oncoprotein, ETV6-NTRK3, which is implicated in cancers of varying lineages. He subsequently completed Physician-Scientist training in the combined MD/PhD program at The University of Texas.
Jackie Harris
Research Administrative Assistant
harrisja@cinj.rutgers.edu
The Gulhati lab is focused on basic and translational research in gastrointestinal cancers. Ongoing projects in the lab are focused on:
Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive and lethal malignancy that will soon be the second leading cause of cancer death and remains remarkably resistant to all forms of therapy. There is a pressing need to gain a deeper understanding of the fundamental biology underlying this recalcitrant disease and uncover novel treatment strategies with sustained therapeutic efficacy.
Visit the Tobacco Dependence Program page to learn how to quit smoking today. Read more
When Patricia Brown needed surgery for her pancreatic cancer, she turned to experts at both Rutgers Cancer Institute and Saint Barnabas Medical Center, enabling her to receive precision care while remaining close to home. Read more
As of April 1, 2024, the following visitation guidelines are in place at Rutgers Cancer Institute for adult and pediatric patients, visitors, staff, and providers. Please note the following: